Ardelyx (ARDX) vs Jade Biosciences (JBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Jade Biosciences (JBIO) has outperformed Ardelyx (ARDX) over the past year, gaining 55.8% versus a loss of 35.4%. Over five years, ARDX leads with a +202.8% price change compared with -97.1% for JBIO. Jade Biosciences is the larger company by market cap ($927.2 million vs $837.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | JBIO |
|---|---|---|
| Share price | $3.25 | $14.58 |
| Market cap | $837.82M | $927.25M |
| 1-day change | -0.76% | +3.04% |
| YTD return | -43.91% | -8.30% |
| 1-year return | -35.38% | +55.84% |
| 5-year return | +202.78% | -97.14% |
| Forward P/E | 11.17 | — |
| EPS (TTM) | $-0.23 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $28.00 |
| 52-week low | $3.18 | $8.36 |
| Distance from 52-week high | -61.37% | -47.93% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +297.53% | +243.83% |
| Average volume | 4.17M | 904.61K |
| Shares outstanding | 258.19M | 63.60M |
| Employees | 489 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JBIO has outperformed ARDX by 91.2 percentage points over the past year.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees
About Jade Biosciences
JBIO stock →Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
ARDX vs JBIO FAQ
Which is bigger, Ardelyx or Jade Biosciences?
Jade Biosciences (JBIO) is larger, with a market capitalization of $927.25M compared with $837.82M for Ardelyx (ARDX).
Which stock has performed better over the past year, ARDX or JBIO?
JBIO returned +55.84% over the past 12 months, compared with -35.38% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and Jade Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.